Idorsia AG (IDIA) CHF0.05

Sell:0.71 CHFBuy:0.71 CHF0.02 CHF (2.54%)

Prices delayed by at least 15 minutes
Sell:0.71 CHF
Buy:0.71 CHF
Change:0.02 CHF (2.54%)
Deal now
Prices delayed by at least 15 minutes
Sell:0.71 CHF
Buy:0.71 CHF
Change:0.02 CHF (2.54%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Key people

Andre C. Muller
Chief Executive Officer, Chief Financial Officer, Member of the Executive Board
Mathieu Simon
Vice Chairman of the Board, Lead Independent Director
Martine Clozel
Executive Vice President, Chief Scientific Officer, Member of the Executive Board
Guy Braunstein
Executive Vice President, Chief Medical Officer, Member of the Executive Board
Alberto Gimona
Executive Vice President, Head of Global Clinical Development, Member of the Executive Board
Jean-Paul Clozel
Chairman of the Board
Bart Filius
Non-Executive Director
Srishti Gupta
Non-Executive Independent Director
Sophie Kornowski
Non-Executive Independent Director
Sandy Mahatme
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Switzerland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CH0363463438
  • Market cap
    CHF 137.75m
  • Employees
    938
  • Shares in issue
    189.47m
  • Exchange
    SIX Swiss Exchange
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.